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DEVELOPMENT OF AN IN-VITRO MODEL OF EQUINE CORNEAL WOUND HEALING; 
PHARMACOLOGIC AND GENE THERAPY MODALITIES IN THE REDUCTION OF CORNEAL 
FIBROSIS 
 
Dylan Buss 
Dr. Elizabeth Giuliano, Thesis Supervisor 
 
ABSTRACT 
 
Objective: To establish an in vitro model for the investigation of equine corneal wound healing. To 
accomplish this goal, a protocol to isolate and culture equine corneal keratocytes, fibroblasts and 
myofibroblasts was developed. Using this model we investigated the safety and efficacy of MMC to treat 
corneal scarring in horses. Additionally, we determined if hybrid adeno-associated virus serotype 2/5 (AAV5) 
vector could effectively deliver foreign genes into the equine cornea without causing adverse side effects.  
Procedure: Using cell culture techniques, equine corneal keratocyte, fibroblast and myofibroblast cultures 
were produced. The MMC dose for the equine cornea was defined with dose-dependent trypan blue 
exclusion and MTT assays after applying MMC to the cultures once for 2 minutes.  The efficacy of MMC to 
control corneal scarring in horses was determined by measuring mRNA and protein expression of corneal 
scarring markers (α-smooth muscle actin and F-actin) with western blotting, immunocytochemistry and/or 
quantitative real-time polymerase chain reactions. AAV5 vector expressing EGFP under control of hybrid 
cytomegalovirus (CMV) + chicken β-actin (CBA) promoter was applied topically to ECF. Expression of 
delivered EGFP gene in ECF was quantified using fluorescent microscopy. Using DAPI staining, the total 
number of cells and transduction efficiency of tested AAV vector was determined. Phase contrast 
microscopy, trypan blue and TUNEL assays were used to determine toxicity and safety of AAV5 for ECFs. 
Results: Cell culture techniques were successfully used to establish a method for the isolation and culture 
of equine corneal keratocytes, fibroblasts and myofibroblasts. A single 2 minute treatment of 0.02% or less 
MMC did not alter ECF phenotype, viability, or cellular proliferation whereas 0.05% or higher MMC doses 
showed mild-to-moderate cellular toxicity.  The TGFβ1 at 1ng/ml showed significant myofibroblast formation 
in ECF under serum-free conditions.  A single 2 minute, 0.02% MMC treatment 24 hours (early) after TGFβ1 
stimulation significantly reduced conversion of ECF to myofibroblasts, however, a single 0.02% MMC 
treatment 11 days after TGFβ1 stimulation showed moderate myofibroblast inhibition. Topical AAV5 
application successfully transduced significant numbers of ECFs. Transduction efficiency was 13.1%. 
vii  
 
Tested AAV5 vector did not cause phenotype change or significant cell death and cell viability was 
maintained. 
Conclusions: Equine corneal stromal keratocytes, fibroblasts and myofibroblasts can be predictably 
isolated and cultured in vitro using this protocol. That MMC safely and effectively reduced scarring in ECF by 
reducing the degree of transdifferentiation of corneal fibroblasts to myofibroblasts in vitro. Tested AAV5 
vector is effective and safe for gene therapy in ECFs in vitro. 
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CHAPTER ONE 
INTRODUCTION 
 
1. EQUINE CORNEAL DISEASE 
Corneal transparency is essential for vision. Due to its position and unique structural 
anatomy, the cornea acts as the eye’s first ocular refractive media, accounting for up to seventy 
five percent of the total refractive state of the eye in terrestrial animals.[1, 2] Therefore, any ocular 
disease that affects the cornea’s transparency affects vision. Corneal disorders are one of the 
most significant causes of vision loss in the horse. Corneal wound healing resulting from 
inflammation, infection, ocular trauma, autoimmune disease or neoplasia, plays a crucial role in 
maintaining corneal transparency. When vision is compromised, a horse’s performance is 
impaired, and treatment is frequently costly and time consuming. 
The equine cornea ranges between 0.8mm and 1.0mm in thickness.[1] It is comprised of 
four basic layers: 1)  epithelium consisting of 8-10 cell layers (~60μm), 2) stroma (~700μm), 3) 
Descemet’s membrane (14-21μm) and 4)  endothelium (7μm).[1] The corneal stroma comprises 
90% of the cornea’s overall thickness and is composed predominately of stromal keratocytes[2]. 
Gap junctions between normal corneal keratocytes and fibroblasts facilitate stability of the stroma 
by supporting physiologic cellular interactions. Corneal trauma resulting in epithelial breakdown 
leads to stromal cell activation, protein synthesis, cytokine release, loss of cell-to-cell contact, and 
culminates in the transformation of local keratocytes and fibroblasts to myofibroblasts.[2, 3]  
Corneal ulceration and scarring is a common ocular problem in horses, resulting in 
significant discomfort and/or permanent vision loss.  Many factors contribute to the frequency of 
corneal ulceration including the size and anatomic location of the equine globe, as well as the 
environmental conditions to which they are exposed.  Treatment of corneal ulceration can be 
costly, labor intensive, and prolonged.[4] Conventional treatment of corneal ulcers in horses 
utilizes topical and systemic therapeutic agents such as antimicrobial/antifungal medications to 
control infection, anti-collagenases to decrease stromal degradation, mydriatics to reduce ciliary 
spasm and stabilize the blood-aqueous barrier, and non-steroidal anti-inflammatory drugs to 
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alleviate ocular pain.[4-6] Corneal wound healing is a complex physiological process involving 
corneal epithelial cell migration and proliferation, keratocyte apoptosis, extracellular matrix 
remodeling, and transdifferentiation of keratocyte to fibroblasts and myofibroblasts.[7, 8] These 
aggregate events play a critical role in the maintenance of corneal structural integrity and 
clarity.[7-10]  Numerous factors, including growth factors, cytokines, and chemokines regulate 
this process.[4, 8] Transforming Growth Factor β (TGFβ1) has been shown to play a key role in 
the conversion of equine corneal fibroblasts (ECF) to myofibroblasts and thus the development of 
corneal scarring.[4, 11] While the production of myofibroblasts is a normal component of this 
complex process, the overproduction of myofibroblasts may be deleterious due to their adverse 
side-effects on corneal transparency. Corneal stromal keratocytes produce and maintain the 
extracellular matrix and actively participate in tissue repair. A change in the stromal environment 
alters keratocyte function.[4, 8] Corneal scar formation is influenced by numerous cytokines and 
results when myofibroblasts are overproduced.[12-14] Myofibroblasts are contractile, 
metabolically active, opaque cells containing intracellular microfilament bundles of F-actin and 
alpha-smooth muscle actin (αSMA).[15] Myofibroblasts are critical to normal corneal wound 
healing.[8, 9] Once wound repair processes are complete, myofibroblast numbers are believed to 
decrease via apoptosis, however the exact pathogenesis is still unknown.[9, 10] Multiple studies 
have shown that a decrease in myofibroblast production reduces corneal fibrosis or haze.[8, 15-
17] 
To the best of our knowledge, no agent specifically used to inhibit equine corneal scarring 
has been investigated.  The lack of a suitable experimental model has been a major limitation to 
these investigations.   
2. GENE DELIVERY IN THE EQUINE CORNEA: A NOVEL THERAPEUTIC STRATEGY 
The cornea is an ideal target tissue for gene therapy because of its accessibility and 
immune-privileged nature.[18-20] The success of gene therapy is contingent upon two variables: 
an appropriate vector and the technique employed to deliver the specific vector into targeted 
tissue. Multiple viral and non-viral vectors have been developed for somatic gene therapy. In 
general, viral vectors offer several fold higher transduction efficiencies and long-term gene 
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expression compared to non-viral vectors.[18, 19] In the last two decades, efficacy of various viral 
vectors such as adeno, adeno-associated (AAV), retro, lenti, and herpes simplex, have been 
examined for introducing DNA into corneal cells in vitro, in vivo and ex vivo.[18-21] Most of these 
studies used fluorescent or non-fluorescent marker genes to track the level and duration of 
transgene expression in cornea.[19] Viral vectors have been associated with toxicity and 
immunogenicity; however, previous studies have demonstrated AAV to be non-pathogenic and 
safe for corneal gene therapy in both the rabbit and mouse.[18, 19, 22]  
Numerous studies have demonstrated AAV to be a safe and efficient method for gene therapy in 
a variety of tissues.[18, 19, 21, 23-25] Among recombinant viral vectors, AAV has shown the 
greatest potential for efficient gene delivery into ocular cells.[19, 20, 26] AAV can transduce 
dividing and non-dividing cells as well as extend long-term transgene expression.[19] Although 
there are more than 100 serotypes of AAV, serotypes 1-9 have been the most commonly 
examined for gene therapy [27, 28]AAV serotypes 2 and 5 have demonstrated a varied degree of 
successful transgene delivery into photoreceptors and retinal pigment epithelial cells of the 
rodent, canine and primate in vivo.[27, 28] Preclinical and clinical gene therapy trials have been 
undertaken for several retinal diseases, including ocular albinism, retinitis pigmentosa and Leber 
congenital amaurosis.[29-33] Compared to literature reports of retinal gene therapy, limited 
studies have been performed to evaluate the usefulness of AAV vectors in corneal gene therapy. 
The efficacy of AAV2 and AAV5 to deliver genes into the corneal stroma of rabbits and rodent in 
vivo has been established.[19]  
Evidence suggests that the major determinant of cellular tropism and transduction 
efficiency of AAV is attributable to the capsid protein. [34] Many hybrid AAV vectors have been 
engineered using capsid protein of AAV serotypes 1-9. AAV5 has proven superior for transgene 
delivery into the retina and cornea compared to AAV2.[28] Our ongoing gene therapy studies in 
mouse and rabbit corneas have demonstrated that AAV5 and AAV8 are relatively more efficient 
at delivering genes into corneal stromal cells compared to AAV2, 6 and 9 serotypes (unpublished 
data, in press, Brain Research Bulletin).         
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3. MYTOMYCIN C 
Mitomycin C (MMC) has been widely used clinically by physician ophthalmologists to 
prevent corneal haze formation that can be a secondary complication after photorefractive 
keratectomy and other refractive laser eye surgeries.[11, 35-38] It has also been advocated by 
physicians for use in treating pterygium and conjunctival and corneal neoplasia.[11] MMC is a 
powerful alkylating agent with potent anti-tumor activity and has the ability to form a covalent 
linkage with DNA to inhibit DNA, RNA, and protein synthesis.[10, 39] MMC has been found to 
significantly inhibit proliferation of corneal epithelial, stromal and endothelial cells, conjunctival 
fibroblasts and retinal pigment epithelial cells.[8, 11, 40-43] Furthermore, studies of MMC have 
demonstrated a significant decrease in corneal haze development by blocking corneal fibroblast 
proliferation, a known mechanism resulting in corneal haze/scar.[11, 44-48] 
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CHAPTER TWO 
EXPERIMENTAL PURPOSE AND HYPOTHESIS 
 
Development of an in vitro model of equine corneal stromal cells is a critical first step in furthering 
our understanding of corneal wound healing in this species. Nonetheless, it is important to note 
that corneal wound healing is a complex process and may require a variety of in vitro models. 
The goal of the first study was to reliably isolate pure cultures of equine corneal keratocytes, 
fibroblasts and myofibroblasts from healthy equine corneal buttons. This model is important to 
future studies to evaluate the effects of topical pharmaceuticals, growth factors, and bacterial 
toxins on equine corneal cell populations. 
In the second study we tested the hypothesis that AAV5 vector could effectively deliver a foreign 
gene into ECFs without causing adverse side effects. Specifically, the aims of this study were to: 
(i) evaluate efficacy of AAV5 expressing enhanced fluorescent green protein (EGFP) marker 
gene for delivering therapeutic genes into ECFs and (ii) establish the safety of AAV5 vector for 
equine corneal gene therapy. 
The purpose of our final study was to examine the anti-fibrotic effects of MMC on equine corneal 
stromal cells.  Specifically, we investigated the safety and therapeutic efficiency of MMC on 
equine corneal scarring at an early and late stage of disease using our previously developed in-
vitro model.  
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CHAPTER THREE 
DEVELOPMENT OF PURE CULTURES OF EQUINE CORNEAL STROMAL CELLS  
AND AN IN-VITRO MODEL OF CORNEAL FIBROSIS 
 
1. MATERIALS AND METHODS 
a. Corneal biopsy collection: 
Full-thickness 6-mm axial corneal buttons were aseptically harvested from five healthy research 
horses undergoing humane euthanasia for reasons unrelated to this study. Slit-lamp 
biomicroscopy was performed by a board certified veterinary ophthalmologist (EAG) prior to 
euthanasia to ensure that all samples were harvested from horses free of anterior segment 
disease. 
 
b. Isolation of equine corneal fibroblasts primary cultures: 
Corneal buttons were washed with minimum essential medium (MEM; Invitrogen, Carlsbad, CA, 
USA) and the epithelium and endothelium was removed by gentle scraping using a #15 Bard 
Parker scalpel blade (BD, Franklin Lakes, NJ, USA). Corneal stroma was sub-sectioned and 
placed in tissue culture plates containing Dulbecco's modified Eagle's medium (DMEM; 
Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum to obtain equine corneal 
fibroblasts (ECF). ECF were then incubated in a humidified 5% CO2 incubator (HERAcell, 
Thermo Scientific, USA) at 37oC. In approximately 3-5 days, fibroblasts began migrating from the 
stromal sub-sections. Once the primary culture reached 90% confluence, the stromal sub-
sections were manually removed using rat-toothed forceps and discarded. The confluent cells 
were trypsinised and re-plated on 60mm tissue plates in customized media at different culture 
conditions to promote growth and differentiation of corneal stromal fibroblasts into keratocytes 
and myofibroblasts.  
 
c. Isolation of equine corneal keratocytes, fibroblasts and myofibroblasts:  
Monocultures of corneal keratocytes, fibroblasts and myofibroblasts were selectively induced 
from the primary cultures generated from corneal explants by altering media or cell seeding 
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conditions. Specifically, a concentration of 50,000 cells per 60mm plate in serum-free MEM 
provided equine corneal keratocyte cultures. Equine fibroblast cultures were selectively produced 
by seeding 50,000 cells per 60mm plate in MEM medium supplemented with 10% fetal bovine 
serum. Myofibroblast cultures were induced from ECF seeding 10,000 fibroblasts per 60mm plate 
in MEM medium supplemented with 10% fetal bovine serum or serum-free MEM medium 
containing 1ng/ml transforming growth factors beta 1 (TGFβ1). The culture parameters 
(temperature, humidity, CO2 etc.) remained the same as those described for obtaining primary 
ECF cultures.  
 
d. Immunohistochemistry for corneal stromal cell markers: 
Immunohistochemistry was used to confirm the presence of equine corneal keratocytes, 
fibroblasts and myofibroblasts. Immunofluorescent staining for both F-actin and α-SMA was 
performed using mouse monoclonal antibody for F-actin (Invitrogen, Carlsbad, CA, USA) and α-
SMA (Invitrogen, Carlsbad, CA, USA). Cultured ECF’s were washed with PBS and incubated at 
room temperature with monoclonal antibody for either F-actin or α-SMA at a 1:200 dilution in 1 x 
PBS for 90 minutes and with secondary antibody Alexa 488 goat anti-mouse IgG (Invitrogen, 
Carlsbad, CA, USA) at a dilution of 1:500 for 1 hour. Cells were mounted with Vectashield 
containing DAPI (Vector Laboratories, Inc., Burlingame, CA, USA) to allow visualization of nuclei. 
Irrelevant isotype-matched primary antibody, secondary antibody alone, and tissue sections from 
naïve eyes were used as negative controls. Immunostained cultures were examined and 
photographed with Leica fluorescent microscope (Leica, Wetzlar, Germany) equipped with a CCD 
digital camera (SpotCam RT KE, Diagnostic Instruments Inc., Sterling Heights, MI, USA). 
 
e. Cellular Morphology and Viability:  
The cellular phenotype of cultures was monitored with a phase-contrast microscope (Leica DMIL) 
equipped with an imaging system (Leica DFC290). The cultures were photographed at different 
time intervals to record cellular morphology. Cellular viability of all cell types was examined using 
trypan blue assay. Briefly, trypsinised cells were mixed with equal amounts of cell biology grade 
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0.4% trypan blue solution (Invitrogen, Carlsbad, CA, USA). Dead cells with ruptured membranes 
stained blue and live white cells were counted using Neubauer’s chamber. Data were expressed 
as percentage of dead cells versus total cell count. 
 
f. Quantification using real-time PCR: 
Total RNA from the cells was extracted using RNeasy kit (Qiagen Inc., Valencia, CA, USA) and 
was reverse transcribed to cDNA following vendor’s instructions (Promega, Madison, WI, USA). 
Real-time PCR was performed using iQ5 real-time PCR Detection System (Bio-Rad Laboratories, 
Hercules, CA, USA). Fifty micro liters reaction mixture containing 2 μL cDNA (250ng), 2 μL 
forward (200nM); 2 μL reverse primer (200nM) and 25 μL 2 X iQ SYBR green super mix (Bio-Rad 
Laboratories) were run at universal cycle (95oC for 3 minutes, 40 cycles of 95oC for 30 seconds 
followed by 60oC for 60 seconds) following the vendor’s instructions. For α-SMA, forward primer 
sequence TGGGTGACGAAGCACAGAGC and reverse primer sequence 
CTTCAGGGGCAACACGAAGC were used. Beta actin forward primer 
(CGGCTACAGCTTCACCACCA) and reverse primer (CGGGCAGCTCGTAGCTCTTC) were 
used as a house keeping gene. The threshold cycle (Ct) was used to detect the increase in the 
signal associated with an exponential growth of PCR product during the log-linear phase. The 
relative expression was calculated using the following formula, 2-∆∆Ct. The ∆Ct validation 
experiments showed similar amplification efficiency for all templates used (difference between 
linear slopes for all templates less than 0.1). Results were expressed as mean ± SEM. Statistical 
analysis was performed using an unpaired student t-test in which P < 0.05 was considered 
significant. 
 
g. Image and Statistical Analysis: 
Statistical analysis was performed using Two-way analysis of variance (ANOVA) followed by 
Bonferroni multiple comparisons test for viability and other assays.  The real-time PCR data 
results were analyzed using one-way ANOVA followed by Tukey’s multiple comparison tests. A 
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“p” value <0.05 was considered significant. The immunocytochemistry data was analyzed using 
image J 1.38 X image analysis software (NIH, USA). 
2. RESULTS 
Light Microscopic Examination: 
Equine corneal fibroblasts, keratocytes and myofibroblasts were cultured using the methodology 
described above. Cultures grown under serum free conditions appeared similar to keratocytes 
that have been described in situ, demonstrating long, broad, stellate cytoplasmic morphology with 
multiple interconnected cellular processes (Figure 1A). By contrast, cells grown in 10% serum 
supplemented medium demonstrated classic spindle shaped fibroblast morphology (Figure 1B). 
Contrary to these observations, equine stromal cell cultures grown in serum-free medium 
containing TGFβ1 (1ng/ml) were larger in size exhibiting the typical myofibroblastic phenotype 
(Figure 1C). Keratocytes had the lowest proliferation rates typical of that observed in vivo in 
equine cornea while corneal fibroblasts had the highest proliferation rates reaching confluence in 
3-4 days. Keratocyte transdifferentiation to myofibroblasts under serum-free condition in the 
presence of TGFβ1 (1ng/ml) was gradual from day 3 to 10. At day-10, over 90% of cells in the 
culture grown in the presence of TGFβ1 (1ng/ml) demonstrated myofibroblastic phenotype 
whereas only 4-8% myofibroblasts were observed in the cultures grown in serum-containing 
(10%) medium. Keratocytes and myofibroblasts achieved confluence in 10-12 days under serum-
free conditions. 
 
Immunocytochemical evaluation: 
Immunocytochemistry examinations of phalloidin (F-actin) and α-SMA staining patterns were 
unique to each of the three examined equine corneal cell phenotypes. The keratocytes appeared 
as a homogenous cell population composed of long, flat, interconnected, stellate cells with F-actin 
staining localized to the cell cortex and occasional or no staining of discernable fibers (Figure 2A). 
Cells in cultures fed with 10% serum-containing medium were spindle shaped and long showing 
typical fibroblastic phenotype with an intracellular staining for F-actin in microfilament bundles 
(Figure 2B).  Myofibroblasts were larger, wider and broader with a substantial increase in the 
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contractile apparatus that stained distinctively and strong for F-actin (Figure 2C). Figure 3 shows 
immunohistochemistry for α-SMA for the equine corneal cell phenotypes. Keratocytes did not 
show positive α-SMA staining (Figure 3A), fibroblasts demonstrated sparse α-SMA staining in few 
cells (Figure 3B) and myofibroblasts revealed extremely high α-SMA staining in all the cells 
(Figure 3C). The sparse α-SMA staining observed in fibroblasts could be attributable to 
myofibroblast contamination. Nonetheless, it is important to mention that even though few 
fibroblast cells (4-8%) in culture showed high α-SMA staining they still retained a predominantly 
fibroblast-like phenotype. It is conceivable that as the populations of cells shift from one 
phenotype to another under specific conditions they may show sparse populations of their 
previous phenotypes. Senescence in any phenotype was not observed during this study.  
 
Viability evaluation: 
The cellular viability of all three phenotypes was greater than 98% as demonstrated by a lack of 
positive trypan-blue staining. These results suggest that the medium composition and culture 
conditions defined for the equine corneal keratocyte, fibroblast and myofibroblast cultures were 
optimal for growing and maintaining these cultures for an extended time. The trypan assay data 
has not been included. 
 
Quantification of Real-time PCR: 
The relative expression of α-SMA quantified using real-time PCR for the three phenotypes has 
been shown in Figure 4. No α-SMA expression was detected in keratocytes whereas 
myofibroblasts showed highest α-SMA levels. The quantity of α-SMA mRNA was found to be 
greater than 1.5 folds in myofibroblasts compared to keratocytes or fibroblasts (p<0.01).  These 
results were consistent with the findings of α-SMA immunocytochemistry. 
3. DISCUSSION 
Corneal disease is one of the most common ocular disorders of horses worldwide.[2, 49] 
Historically in veterinary ophthalmology, treatment has focused primarily on globe preservation 
and restoration of ocular comfort and lesser on the restoration of normal vision, particularly in 
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cases of severe keratitis. Treatment strategies aiming specifically at the reduction of corneal 
scarring are grossly lacking in the horse. Corneal scarring or “haze” as it is referred to in 
physician ophthalmology, has been the topic of numerous studies. In hopes of reducing haze in 
patients who undergo photorefractive laser eye surgery (PRK, LASIK etc), experimentation in 
mouse, rabbit and human corneas have been completed. Mitomycin C has been proven to be 
effective at reducing haze.[11, 37, 45, 46, 48, 50] Recently, Trichostatin A has proved effective in 
blocking the effect of TGFβ1 and thereby reducing corneal haze.[51] Gene therapy is a new 
treatment modality which is demonstrating promise. The decorin gene has been inserted into an 
adeno-associated virus (AAV) vector that has successfully transduced rabbit corneal fibroblasts 
and blocked the fibrotic effects of TGFβ1, thereby reducing corneal fibrosis in vitro.[52] 
An in vitro model is therefore highly desired for studying wound healing events in the 
equine cornea and testing the efficacy of potential therapeutic agents for the prevention and 
treatment of corneal scarring in horses. To the best of authors’ knowledge there have been no 
previous reports of an in vitro equine corneal wound healing model. Haber et al., examined the 
effects of growth factors (EGF, PDGF-BB and TGF-beta 1) on cultured equine epithelial cells and 
keratocytes [4, 53] ; however, our investigation differs in that our goal was to successfully 
establish three separate, reproducible cell lines from equine stroma only. This study reports 
optimal conditions for growing equine corneal keratocytes, fibroblasts and myofibroblasts that 
serve as a model for studying equine corneal wound healing. The proliferation rates, morphology, 
distribution of F-actin and α-SMA marker proteins were similar to those results published for 
keratocytes, fibroblasts and myofibroblasts from other species (canine and rabbit).[2, 9, 53] We 
were able to establish the growth of ECF by culturing corneal stromal subsections at cellular 
density of 50,000 cells/60mm plate in the presence of serum. The keratocyte phenotype was 
induced by culturing the ECF under serum-free conditions whereas equine corneal myofibroblast 
cultures were obtained by plating the ECF at a lower density (10,000 cells/60mm plate) in the 
presence of serum or in TGFβ1 under serum-free conditions. These findings are consistent with 
those reported previously in rabbits and humans.[11, 54]  
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Immunohistochemical staining confirmed cell phenotypes via staining patterns of F-actin 
(Figure 2) and α-SMA (Figure 3). Keratocytes are quiescent cells not requiring a significant 
contractile apparatus. Therefore, the presence of F-actin is less prominent and localized to the 
cortex of this cell type. Once activated, keratocytes can quickly develop higher levels of F-actin in 
an organized arrangement typical of their transformation into fibroblasts. The result is a 
morphological change from stellate to spindle shaped. F-actin staining in fibroblasts 
demonstrated an increase in F-actin which was more evenly distributed throughout the cytoplasm 
in visible bundles. Differentiation of myofibroblasts results in further cellular enlargement due to 
activation of protein synthesis and a greater increase in F-actin containing α-SMA, alpha-actinin 
and myosin. F-actin staining of myofibroblasts demonstrated prominent intra-cellular bundles 
indicative of a well-developed contractile apparatus. The increase in α-SMA yielded characteristic 
myofibroblast staining patterns not observed in either keratocyte or fibroblast cell culture 
populations. 
This novel research model has similar benefits to other established in vitro models 
including: practicality, reproducibility, high proliferation rates, ability to control study environment, 
and the possibility of cell line cryopreservation.[54-59] Multiple in vitro and in vivo studies 
performed in experimental animals have significantly increased our understanding of cellular and 
molecular mechanisms involved in the development of corneal haze following keratitis.[4, 60] 
Keratitis causes an alteration in the natural conformation of extracellular matrix and also changes 
the cellular density and phenotype of keratocytes.[4] These factors result in decreased corneal 
tissue transparency, commonly referred to as corneal haze.[60] The generation of corneal 
myofibroblast cells has recently been identified as the primary biological event responsible for the 
formation of corneal stromal opacification.[4, 8, 11, 61] Myofibroblasts are highly contractile cells 
with increased backscattering of light attributable to decreased intracellular crystallin 
production.[62] Induction of myofibroblasts in corneal stroma plays a significant role in corneal 
fibrosis and long-term reduction in a clear visual axis. 
In summary, the purpose of isolating and culturing equine corneal stromal fibroblasts, 
keratocytes, and myofibroblasts was to establish a reproducible in vitro model of pure cultures of 
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these three cell types. This model will allow further investigation into the study of equine corneal 
wound healing. Investigations using anti-fibrotic agents and gene therapy are currently underway 
using this model.  
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CHAPTER 4 
 GENE DELIVERY IN THE EQUINE CORNEA: A NOVEL THERAPEUTIC STRATEGY 
 
1. MATERIALS AND METHODS 
a. Equine corneal fibroblast culture: 
Full-thickness 6-mm axial corneal buttons were aseptically harvested from healthy research 
horses undergoing humane euthanasia for reasons unrelated to this study. Slit-lamp 
biomicroscopy was performed by a veterinary ophthalmologist (EAG) prior to euthanasia to insure 
that harvested corneal tissues were collected from horses free of any anterior segment disease. 
Corneal samples were washed with serum-free Dulbecco’s modified Eagles medium 
supplemented with antibiotics (penicillin-streptomycin). The epithelium and endothelium were 
removed by gentle scraping with a #15 scalpel blade. Using sharp dissection, the remaining 
corneal stroma was sub-sectioned into 2mm sections and placed on tissue culture dishes in a 
humidified CO2 incubator at 37 degrees Celsius in Dulbecco’s modified Eagles medium (DMEM) 
containing 10% fetal bovine serum for several weeks to obtain primary cultures of ECFs.  
 
b. AAV vector production: 
AAV serotype 5 expressing EGFP under control of hybrid cytomegalovirus (CMV) + chicken β-
actin (CBA) promoters (AAV5-pTRUF11-EGFP) was utilized for all experiments and obtained 
from Prof. Gregory Schultz and Prof. William Hauswirth, Gene Therapy Core, University of 
Florida, Gainesville, Florida. Construction of an AAV5 vector containing the enhanced green 
fluorescent protein (EGFP) reporter gene was performed according to standard helper-dependent 
techniques using adenovirus free system.[18]  
 
c. AAV vector and ECF transduction: 
Seventy-percent confluent cultures of ECFs in 12-well plates were used for all the experiments. 
Cultures were serum deprived for 2 hrs prior to viral transduction (viral titer of 109 genomic 
copies/micro liter) and two microliters of AAV serotype 5 expressing EGFP marker gene under 
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control of hybrid CMV + CBA promoters were added to ECF cultures via topical application in 
serum free medium at a multiplicity of infection (MOI) of 105 and 2 x 105. After 6 hrs, the medium 
containing viral vector was replaced with fresh serum-containing medium and the cells were 
incubated for 2 days prior to microscopic evaluation of fluorescence.   
 
d. AAV safety: 
Light microscopy images were obtained to observe any phenotypic or morphologic changes in 
ECF cultures after the application of AAV5.  TUNEL assay was used to detect fibroblast 
apoptosis due to AAV vector transduction. ECF cells were fixed in Paraformaldehyde at room 
temperature for 5 minutes and then washed in phosphate buffered saline. A fluorescence-based 
TUNEL assay was used according to the manufacture’s instructions using ApopTag apoptosis 
detection kit (Chemicon international, Temecula, CA, USA). Cellular viability was assessed using 
a trypan blue (Sigma-Aldrich, St. Louis, USA) administered 48 hrs after transduction. Trypan blue 
dye staining dead cells blue and viable cells staining white were counted microscopically in a 
hemocytometer. 
 
e. AAV transduction efficiency: 
EGFP transduced ECF cells and DAPI-nuclei in culture were counted using direct fluorescence 
microscopy at 100X magnification in ten randomly selected, non-overlapping areas for each 
treatment. Analysis was performed on a PC computer using the public domain NIH Image 
program (developed at the U.S. National Institutes of Health and available on the Internet at 
http://rsb.info.nih.gov/nih-image). Percent transduction efficiency was calculated by dividing the 
total number EGFP positive cells by that of the total number of DAPI stained nuclei.  
 
f. Statistical Analysis: 
Results were expressed as mean ± standard error of the mean (SEM). Statistical analysis was 
performed using two-way analysis of variance (ANOVA) followed by Bonferroni test for comparing 
data between control and AAV vector.  
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2. RESULTS 
AAV safety: 
Cultured ECFs demonstrated a classic spindle shaped morphology. No observable changes in 
light microscopic morphology were detected at any time point after successful transduction with 
AAV5 (Figure 5 A-D). Throughout the study period, both the control and the AAV transduced 
populations continued to demonstrate a healthy spindle shaped morphology and progressed 
normally to confluence.  
Trypan blue exclusion assay demonstrated cellular viability of AAV-treated and untreated ECFs 
between 96-98% at all three tested time points (8hrs, 24hrs and 48hrs) after AAV transduction. 
Recall that transduction efficiency was established at the 48 hour time point. The results of 
cellular viability determined with trypan blue assay are shown in Figure 6. The safety of AAV5 
vector for ECF was further established by determining its effects on cell death with TUNEL assay. 
No detectable cellular apoptosis was detected using this method (results not shown).  
 
AAV transduction efficiency: 
We were able to demonstrate the successful transduction of a foreign gene, EGFP, into ECF cells 
with topically applied AAV5 via fluorescent microscopy. Figure 7A-C demonstrates green 
fluorescence in a spindle shaped morphology in successfully transduced ECF cells against the 
blue DAPI-stained nuclei of the ECF cells. Quantification of this data was completed at 100x 
magnification using the previously described method and is displayed in Figure 7. This data 
demonstrates a significant transduction efficiency of 13.1% using AAV5 in ECF in vitro. 
3. DISCUSSION 
Corneal gene therapy represents a novel approach to the potential treatment of a wide 
variety of keratopathies. It may provide an opportunity to target the specific underlying cause of a 
corneal disorder as opposed to simply treating the symptoms as with conventional 
pharmaceuticals. Furthermore, its therapeutic benefits are evident long-term, even after a single 
treatment versus the required repeated applications for long periods with conventional small 
molecule drug therapy.[19] Gene therapy for equine corneal disease is a new application of this 
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developing technology. Common equine corneal diseases include traumatic, inflammatory, 
neoplastic and infectious forms of keratitis.. For many of theses conditions, particularly when 
severe, therapeutic goals are directed at preserving the globe and relieving ocular discomfort and 
to a lesser extent toward re-establishing clear corneal transparency. Many of these keratidities 
require labor-intensive treatments which can be difficult for both horse and owner. Gene therapy 
could provide an alternative to traditional small molecule therapy or be used adjunctively to 
improve corneal transparency and long-term visual success.  
This is the first study to evaluate the transfection efficiency of AAV into ECFs. AAV5 was 
selected in this study because of its availability, enhanced transgene delivery, and low cellular 
toxicity. As this was the initial testing of AAV on ECFs, an in vitro model was used. In vitro models 
are economical, practical, easily maintained, and allow the investigator precision in control of 
experimental conditions. The transduction efficiency of AAV5 serotype determined in vitro for 
various cell types such as lung epithelium, skeletal muscle, gastrointestinal cells, and corneal 
fibroblasts was similar to that studied in vivo.[63-65] Thus, it is reasonable to conclude that an in 
vitro model can provide highly relevant and beneficial information regarding the efficacy of the 
AAV vector for gene therapy in vivo.[66]  Based on our earlier in vivo studies performed in mouse 
and rabbit corneas with selected AAV5 vector, we speculate that tested AAV5 vector will 
demonstrate similar gene transfer efficacy into equine stroma in vivo without causing significant 
side effects.[18, 19] Further studies examining the potential of selected AAV5 vector to deliver 
therapeutic genes into the equine cornea in vivo are warranted. 
Many laboratories, including ours, have demonstrated that recombinant AAV2 vectors 
can efficiently transport foreign genes in the cornea, retina, and various other ocular tissues. [19, 
27, 28] However, enhanced gene transfer has been noted with the hybrid AAV vectors developed 
subsequently by combining AAV2 genome with capsid proteins of other AAV serotypes (1-9). The 
hybrid AAV vectors were found superior to the conventional recombinant AAV vectors in regards 
to transduction efficiency and safety.[19, 24, 65, 67] Also, hybrid vectors demonstrated unique 
tropism and variable transduction efficiencies for differing target tissues. For example, AAV 2/9 
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hybrid vector was more efficient at gene delivery in cardiac muscle cells compared to AAV2/1, 
AAV2/6, AAV2/7 and AAV2/8. Gao et al[68] found that AAV 2/8 had a 200 fold higher transgene 
delivery into liver cells compared to AAV2 vector. Interestingly, AAV2/6 hybrid vector was more 
efficient at gene delivery into muscle cells than the AAV2/5 or AAV2 vector.[64] This pattern of 
cellular tropism and subsequent differences in gene efficiency has been documented with AAV in 
ocular tissues. The corneal stroma, photoreceptors, and retinal pigmented epithelium showed 
higher levels of delivered-gene expression with AAV2/5 compared to the AAV2 vector.[28] The 
current literature suggests that further evaluation using different hybrid AAV vectors developed by 
combining AAV2 genome with various AAV serotypes capsids (AAV1-9) for the ECFs is also 
warranted.  
A transduction efficiency of 13.1% was noted for the ECFs with the tested hybrid AAV2/5 
vector in this study. Due to lack of current experimental evidence it is unknown whether this rate 
of transduction is of therapeutic value for the equine cornea. We hypothesize that moderate 
transduction efficiency ranging from 12-20% will be sufficient to treat corneal diseases in horse. 
Future investigations will test this hypothesis. Based on the results of our gene transfer 
investigations performed in mice and rabbit corneas in vivo, and human corneas ex vivo we 
speculate that for achieving maximum gene transduction in the equine cornea in vivo direct 
contact of AAV to the stroma for a short duration (2-10 minutes) may be required. AAV applied 
topically on the mouse or rabbit cornea with intact epithelium showed considerably low AAV 
penetration in the stroma compared to the corneas that received AAV after removing the 
epithelium.[18] Also, corneas receiving AAV after epithelial removal showed transduction 
predominantly in anterior stroma and minimal in the posterior stroma. Gene therapy to treat 
corneal ulceration and scarring is clinically relevant as most myofibroblast formation is observed 
in the anterior stroma [11] except in the cases of very severe, deep ulceration. The 
immunogenicity of tested AAV5 vector in vivo also needs to be established. Of note, tested AAV5 
vector did not cause clinically significant immune reactions in mouse or rabbit eyes in vivo, 
suggesting that similar results could be observed in vivo in horses.[19] In this in vitro study, 
testing of AAV5 resulted in no detectable adverse effects (i.e. loss of cellular viability, cell death, 
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and/or phenotype change). Future studies may examine the effects of different viral 
concentrations, viral incubation times, and comparison of the transduction efficiencies of several 
serotypes.  
Gene therapy provides many possible therapeutic options depending on the gene being 
transduced. Potential areas of therapy include inserting the decorin gene into ECF.[52] The 
decorin gene is known to silence the effects of TGFβ, which causes transformation of ECF to 
myofibroblasts and haze in the cornea.[11] The reduction in myofibroblast formation could then 
reduce the development of a corneal scar, a very common sequela to equine corneal ulceration. 
Another approach would be to deliver fibroblast growth factor (FGF2) gene with AAV in the face 
of a developed corneal scar or chronic corneal ulcer to reduce the established corneal scar. 
FGF2 has been shown to revert myofibroblasts to corneal fibroblast using an in vitro model.[14] 
Additional possibilities include modification of cytokine production in the cornea. For example 
Morrison et al., used an AAV vector to increase IL-10 in the lung of pigs with Actinobacillus 
pleuropneumoniae and found a reduction in mortality and morbidity due to the decrease in 
macrophage activation which typically leads to significant lung pathology.[69] In cases of severe 
equine infectious keratitis, specifically where keratomalacia is present, the immune response is 
fulminant and possibly over stimulated. Delivering a therapeutic gene to increase expression of 
IL-10 could reduce the immune response and if so, have clinical relevance. Greenberger et al., 
used an AAV vector to increase IL-12 gene expression in tracheal epithelial cells of mice infected 
with Klebsiella. IL-12, a pro-inflammatory cytokine stimulates an immune response.[70] In certain 
cases of equine corneal disease there appears to be a lack of an immune response. As a result 
these cases can take months to heal and may require surgical intervention to aid in the process. 
An AAV vector which could introduce an IL-12 gene to increase an immune response may be of 
benefit. The advantages of gene therapy by delivering a gene or gene products such as Flt23K, 
endostatin, kringle-5 domain of plasminogen, angiostatin, IL12, or IL10, to reduce corneal 
neovascularization has been demonstrated using experimental animal models.[71] Additionally, 
gene therapy has great potential for developing vaccines by delivering DNA encoding for HSV-1 
glycoproteins, such as glycoprotein (g) D, gB1, or a cocktail of glycoproteins in an effort to 
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increase immunity against HSV-induced ocular keratitis.[71] This same biotechnology has the 
potential to be applied to equine patients inflicted with equine herpes keratitis. 
To our knowledge, this is the first study to demonstrate that AAV5 can effectively 
transduce ECFs, making AAV-mediated gene therapy a plausible method for treatment of equine 
corneal disease.   
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CHAPTER 5 
 
MITOMYCIN C, A POTENT AGENT TO TREAT CORNEAL SCARRING  
IN HORSES IN-VITRO 
 
 
1. MATERIALS AND METHODS 
a. Equine corneal fibroblast, keratocyte and myofibroblast cultures 
Five full-thickness 6-mm axial corneal buttons were aseptically harvested from healthy research 
horses undergoing humane euthanasia for reasons unrelated to this study.  Slit-lamp 
biomicroscopy was performed by a board-certified veterinary ophthalmologist (EAG) prior to 
euthanasia to ensure that all samples were harvested from horses free of anterior segment 
disease.  Corneal buttons were washed with minimum essential medium (MEM; Gibco, 
Invitrogen, Carlsbad, CA, USA) and the epithelium and endothelium was removed by gentle 
scraping using a #10 Bard Parker scalpel blade (BD, Franklin Lakes, NJ, USA).  Corneal stroma 
was sub-sectioned and placed in tissue culture plates containing Dulbecco's modified Eagle's 
medium (DMEM; Gibco, Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum to 
obtain ECF.  ECF were then incubated in a humidified CO2 incubator (HERAcell, Thermo 
Scientific, USA) at 37oC.  In approximately 3-10 days, fibroblasts began migrating from the 
stromal sub-sections.  Once the primary culture reached 90% confluence, the stromal sub-
sections were manually removed using rat-toothed forceps and discarded.  The confluent cells 
were trypsinized and re-plated on 60 mm tissue plates.  Passages 1-3 of ECF were used for this 
experiment.  The monocultures of corneal keratocytes, fibroblasts and myofibroblasts were 
selectively induced from the primary cultures generated from corneal explants by altering media 
or cell seeding conditions.  Specifically, a concentration of 50,000 cells per 60 mm plate in serum-
free MEM provided equine corneal keratocyte cultures.  Equine fibroblast cultures were 
selectively produced by seeding 50,000 cells per 60 mm plate in MEM medium supplemented 
with 10% fetal bovine serum.  Myofibroblast cultures were induced from seeding 10,000 
fibroblasts per 60 mm plate in MEM medium supplemented with 10% fetal bovine serum or 
serum-free MEM medium containing 1ng/ml TGFβ1.  
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b. Cytotoxicity studies 
The cytotoxicity of MMC to ECF was evaluated using phase-contrast microscopy and Trypan 
blue, MTT and TUNEL assays.  Microscopy was used to evaluate cellular morphological 
changes, Trypan blue and MMT assays assessed cellular viability, and TUNEL assay detected 
apoptotic cells in cultures.  Microscopy investigations utilized a phase-contrast microscope (Leica 
DMIL) equipped with an imaging system (Leica DFC290).  The ECF cultures treated with MMC 
were examined at different time intervals and cell morphology was recorded using digital 
photography. 
 Trypan blue assay was performed following manufacturer’s instructions.  Briefly, at 
selected time points, cells were trypsinised and mixed with equal amounts of 0.4% trypan blue 
solution (Invitrogen, Carlsbad, CA, USA).  Dead cells with ruptured membranes stained blue and 
live cells white were counted with Neubauer’s chamber. Cellular viability was calculated as a 
percent. The MTT assay is colorimetric assay which utilizes a tetrazolium compound, MTT 
(Sigma-Aldrich, St Louis, MO).  The MTT is bio-reduced by viable cells to a purple color formazan 
product which is detected at an absorbance of 570 nm by spectrophotometry.  Ten μl of MTT 
reagent was added the each well of 96-well plate containing 100 μl DMEM and 70% confluent 
ECF cultures treated with or without MMC.  Wells containing media alone without cells served as 
negative controls.  Plates were incubated at 37°C in a humidified 5% CO2 incubator and 
absorbance was recorded at 570 nm (BioTEk FLx 800, Winooski, VT, USA).  
A fluorescence-based TUNEL assay was used to detect DNA fragmentation and 
apoptosis in ECF.  The MMC treated and untreated ECF cultures were fixed in acetone at -20oC 
for 2 minutes, dried at room temperature for 5 minutes, and placed in PBS balanced salt solution.  
Apoptosis was detected with ApopTag apoptosis detection kit (Millipore, Billerica, MA, USA) 
following manufacturer’s instructions.  Photographs were obtained using a fluorescent 
microscope (Leica, Wetzlar, Germany) equipped with a digital camera (SpotCam RT KE, 
Diagnostic Instruments Inc., Sterling Heights, MI, USA). 
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c. Immunocytochemistry and quantification of anti-fibrotic effect of MMC 
Immunofluorescent staining for αSMA, a marker for myofibroblasts responsible for corneal 
fibrosis, was performed using mouse monoclonal antibody for αSMA.  The myofibroblast 
formation in ECF was stimulated with TGFβ1.[66] To evaluate anti-fibrotic effect of MMC, 0.02% 
MMC was added to cultures for 2 minutes once at 24 hours (early) after TGFβ1 stimulation or at 
11 days (late) after TGFβ1 stimulation.  A single 0.02% MMC treatment for 2 minutes 
demonstrated least toxicity to ECF.  At study end-point, cultures were washed twice with PBS and 
incubated at room temperature with mouse monoclonal antibody for F-actin (Invitrogen, Carlsbad, 
CA, USA) αSMA (DAKO, Carpinteria, CA, USA) at a 1:200 dilution in 1X PBS for 90 minutes and 
with secondary antibody Alexa 488 or 594 goat anti-mouse IgG (Invitrogen, Carlsbad, CA, USA) 
at a dilution of 1:500 for 1 hour.  Cells were mounted with Vectashield containing DAPI (Vector 
Laboratories, Inc., Burlingame, CA, USA) to allow visualization of nuclei. Irrelevant isotype-
matched primary antibody, secondary antibody alone, and tissue sections from naïve eyes were 
used as negative controls.  Tissue culture plates were examined and photographed with Leica 
fluorescent microscope (Leica, Wetzlar, Germany) equipped with a digital camera (SpotCam RT 
KE, Diagnostic Instruments Inc., Sterling Heights, MI, USA) at the conclusion of the study.  The 
αSMA and DAPI-stained cells in ten randomly selected areas were counted per 400X microscope 
field. 
 
d. Immunoblotting 
ECF were washed with ice-cold PBS and lysed in RIPA lysis buffer containing protease inhibitor 
cocktail (Roche Applied Sciences, Indianpolis, IN, USA).  The samples were suspended in 
Laemmli’s denaturing sample buffer (30 μl) containing β-mercaptoethanol, vortexed for 1 minute, 
centrifuged for 5 minutes at 10,000x g, and boiled at 70°C for 10 minutes.  Protein samples were 
resolved by 4%–10%SDS–PAGE and transferred to a 0.45-μm pore size PVDF membrane 
(Invitrogen, San Diego, CA).  The membrane was incubated with αSMA (DAKO, Carpinteria, CA, 
USA), fibronectin or GAPDH primary antibodies (Santa Cruz Biotechnology Inc, Santa Cruz, CA, 
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USA) followed by secondary anti-mouse-or goat antibodies (Santa Cruz, Biotechnology Inc, 
Santa Cruz, CA, USA). 
 
e. RNA extraction, cDNA synthesis and quantitative real-time PCR  
The total RNA from ECF was extracted using RNeasy kit (Qiagen Inc., Valencia, CA, USA) and 
reverse-transcribed to cDNA following manufacturer’s instructions (Promega, Madison, WI, USA).  
Real-time PCR was performed using iQ5 real-time PCR Detection System (Bio-Rad Laboratories, 
Hercules, CA, USA). A 50 µL’s reaction mixture containing 2 µL cDNA (250ng), 2 µL forward 
(200nM), 2 µL reverse primer (200nM), and 25 µL 2X iQ SYBR green super mix (Bio-Rad 
Laboratories) was run at universal cycle (95oC 3 min, 40 cycles of  95oC 30 sec followed by 60oC 
60 sec) following manufacturer’s instructions.  For αSMA, forward primer sequence 
TGGGTGACGAAGCACAGAGC and reverse primer sequence CTTCAGGGGCAACACGAAGC 
were used.  The house keeping gene beta actin forward primer sequence was 
CGGCTACAGCTTCACCACCA and reverse primer sequence was 
CGGGCAGCTCGTAGCTCTTC.  The threshold cycle (Ct) was used to detect the increase in the 
signal associated with an exponential growth of PCR product during the log-linear phase. The 
relative expression was calculated using the following formula: 2-ΔΔCt.  The ΔCt validation 
experiments showed similar amplification efficiency for all templates used (difference between 
linear slopes for all templates less than 0.1).  Three independent reactions were performed and 
the average (± SEM) results were calculated. 
 
f. Image and statistical analysis 
The results were expressed as mean ± standard error of the mean (SEM).  Statistical analysis 
was performed using two-way analysis of variance (ANOVA) followed by Bonferroni multiple 
comparisons test for cell toxicity assay.  The real-time PCR data results were analyzed using 
one-way ANOVA followed by Tukey’s multiple comparison tests.  A p-value less than 0.05 was 
considered significant.  The immunoblotting data was analyzed using image J 1.38 X image 
analysis software (NIH, USA). 
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2. RESULTS 
Cellular Viability 
The experimental data collected from dose-dependent trypan blue and MTT assays presented in 
Figure 8.  A single 2 minute, 0.02% MMC treatment dose was the most effective dose at reducing 
myofibroblast formation in ECF. One 0.02% MMC treatment to ECF on day-1 (early) or day-11 
(late) did not alter ECF cellular viability (Figure 8) or phenotype (Figure 9).  No statistically 
significant differences in the MMC treated or untreated control groups were noted. 
Apoptosis 
The TUNEL assay detected increased apoptotic cell death in ECF cultures treated with 0.02% 
MMC early (Figure 10B) and late (Figure 10D) compared to untreated controls (Figure 10A and 
10C).  Although relatively more apoptosis was detected in the late MMC group when compared to 
the early MMC group, the percent of apoptotic cells between the two groups was not statistically 
significant.  We believe that lack of statistical difference is due to the higher ECF density in late 
treatment group (Figure 10C and 10D) compared to the early treatment group (Figure 10A and 
10B) as evident from DAPI nuclear staining (Figure 10).  The late ECF treatment group received 
MMC on day-11 whereas the early ECF treatment group received MMC on day-1.  These findings 
are consistent with our in-vivo rabbit studies that showed reduction in corneal scarring with MMC 
was due to increased apoptosis and decreased cellular proliferation.[11]  
F-actin immunocytochemistry 
F-actin immunostaining of treatment groups was photographed (Figure 11).  The ECF grown in 
absence of TGFβ1 (normal fibroblasts) showed mild F-actin staining in microfilament bundles 
(Figure 11A) whereas ECF grown in presence of TGFβ1 (myofibroblasts) showed prominent 
intracellular staining of F-actin in large microfilaments bundles of contractile apparatus (typical of 
myofibroblasts, Figure 11B).[66]  A single 2 minute, 0.02% MMC application to ECF in the early 
treatment group demonstrated a significant decrease in F-actin staining, consistent with marked 
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reduction in contractile apparatus formation (Figure 11C).  However, the same MMC dose 
showed a moderate reduction in F-actin staining in late treatment group (Figure 11D). 
αSMA immunocytochemistry, quantification and western blotting 
Immunocytochemistry of αSMA was performed on all experimental groups (Figure 12). No αSMA 
was detected in ECF grown in absence of TGFβ1 (Figure 12A).  By contrast, high levels of αSMA 
were detected in ECF grown in presence of TGFβ1 (Figure 12B).  One 2 minute application of 
0.02% MMC to ECF on day-1 (early treatment group) showed substantial inhibition of TGFβ1-
induced transdifferentiation of ECF to myofibroblasts (Figure 12C). However, similar MMC 
treatment performed on day-11 (late treatment group) did not appear effective and showed only 
moderate inhibition of ECF to myofibroblasts (Figure 12D).  
Quantification of αSMA immunocytochemical data is summarized in Figure 13.  The ECF 
grown under serum-free conditions in the presence of TGFβ1 (1ng/ml) showed significantly high 
levels of αSMA staining (65-81%; p < 0.01) in the cells compared to control ECF grown in the 
absence of TGFβ1 (<2%).  One 2 minute 0.02% MMC application to ECF significantly decreased 
TGFβ1-induced myofibroblast development in early (69% ± 5.8; p < 0.01) and late (28% ±9.8) 
treatment groups (Figure 13). 
Figure 14 demonstrates measurement of αSMA protein with western blot analysis.  The analysis 
of data after normalization further confirmed the anti-fibrotic effect of MMC on ECF. The 0.02% 
MMC treatment to ECF grown in presence of TGFβ1 under serum-free conditions effectively 
suppressed αSMA expression in both the early (≤ 65%) and late (≤ 30%) treatment groups.  
αSMA RNA quantification 
Figure 15 shows quantification of αSMA RNA performed with real-time PCR.  A statistically 
significant 23-fold increase in αSMA RNA was detected in ECF exposed to TGFβ1 and no 
change in ECF not exposed to TGFβ1 (Control). The early application of MMC demonstrated a 
significant 14-fold reduction of αSMA RNA (p < 0.01). 
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3. DISCUSSION: 
Corneal scarring or fibrosis is a common sequela to corneal disease and frequently 
results in vision deficits.[4, 6] Historically in veterinary ophthalmology, our therapeutic efforts have 
been focused on globe preservation and restoration of ocular comfort. Treatment options for 
horses specifically geared towards prevention and/or the reduction of corneal fibrosis are lacking.  
In-vitro studies represent a highly valuable tool to further our understanding of the physiologic 
mechanisms of corneal wound healing.  In-vitro models represent an ideal controlled setting to 
test drug development with potentially clinically relevant applications.  Corneal fibrosis involves 
keratocyte apoptosis, proliferation and transdifferentiation of fibroblasts into myofibroblasts.[51, 
72] Smooth muscle actin expression and deposition of extracellular matrix protein in a random 
pattern are primarily responsible for corneal fibrosis and resultant visual opacity.[9, 51] Numerous 
studies in various animal models have demonstrated the role of TGFβ1 in the development of 
corneal fibrosis.[11, 12, 51, 73, 74] Additionally, it has been established that anti-TGFβ1 
antibodies have reduced the production of corneal haze in rabbits which had received 
photorefractive keratotomy (PRK).[75] Several reports have been published demonstrating the 
effectiveness of MMC to reduce corneal fibrosis in rabbit, rodent and human corneas both in-vivo 
and in-vitro.[11, 47, 48]  
Current literature reviews found only one report regarding the use of MMC on the equine cornea. 
Rayner and Van found MMC effective for equine corneal squamous cell carcinoma (0.4mg/ml 
MMC intraoperatively on the affected areas for 1 or 5 minutes).[76]  In that report, no mention 
was made pertaining to the anti-fibrotic effects of MMC.  To the best of our knowledge this 
publication represents the first investigation of the anti-fibrotic effects of MMC on equine corneal 
cells using an in-vitro model.  Our data demonstrate the ability of MMC to reduce myofibroblast 
production in ECF cultures and its effectiveness when applied at an early or late stage of disease 
(e.g., reduction in the αSMA and F-actin levels; Figures 4-8).  Significant suppression of 
myofibroblast production was noted when MMC was applied at an early stage of disease 
compared to a late stage consistent with the fact that the anti-fibrotic effects of MMC are due to 
the inhibition of cellular proliferation and induction of apoptosis.[7-9, 11, 12, 77] Although 
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relatively more apoptosis was detected in the late MMC group when compared to the early MMC 
group, the percent of apoptotic cells between the two groups was not statistically significant.  We 
believe that lack of statistical difference is due to the higher ECF density in late treatment group 
(Figure 10C and 10D) compared to the early treatment group (Figure 10A and 10B) as evident 
from DAPI nuclear staining (Figure 10).  The late ECF treatment group received MMC on day-11 
whereas the early ECF treatment group received MMC on day-1.  These findings are consistent 
with our in-vivo rabbit studies that showed reduction in corneal scarring with MMC was due to 
increased apoptosis and decreased cellular proliferation.[11] Our data support previously 
published reports where significant inhibition of corneal scarring in humans and rabbits in-vitro 
and in-vivo has been demonstrated.[10, 16, 17, 35-38] It is reasonable to expect that MMC may 
be useful clinically for the reduction of corneal fibrosis in equine patients.  MMC treatment in the 
face of an established corneal scar may prove less beneficial compared to topical MMC 
application at the time of corneal ulceration diagnosis or keratectomy; however, clinical trials are 
needed to further assess the usefulness of its application in equine patients.   
While the effectiveness of MMC against corneal haze is well-established, conflicting reports 
regarding its safety in human patients can be found.[43-48]  Several different protocols, involving 
different concentrations and exposure times, have been suggested or used by clinicians to 
minimize unwanted side effects of MMC.[11, 76, 78] This pilot study addressed the safety of 
MMC for the equine cornea in an in-vitro model by evaluating the response of MMC on ECF 
morphology and the proliferation and cell death using various biochemical assays.  In this study, 
the 0.02% dose of MMC was deemed safe for the equine cornea because it did not induce 
significant apoptosis or alter ECF proliferation or phenotype (Figures 8-10).  MMC may prove 
beneficial in the reduction of corneal fibrosis secondary to corneal injury in the equine patient and 
improve long-term visual outcome.  Further studies are warranted to determine optimal MMC 
dosing for treatment of corneal fibrosis in the clinical patient.  
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APPENDIX 
FIGURES 
Figure 1: Light microscopy phase‐contrast images of (A) keratocytes demonstrating broad, 
stellate cytoplasmic morphology with multiple interconnected cellular processes, (B) fibroblasts 
demonstrated a classic spindle shaped morphology, as did (C) myofibroblasts; however this 
phenotype was larger in overall size due to the developed contractile apparatus. Calibration 
Bar=100μm  
 
Figure 2: Immunocytochemical staining with phalloidin (red) showing expression and localization 
of F-actin in equine keratocytes, fibroblasts and myofibroblasts. Nuclei are stained blue by DAPI. 
Kertatocytes (A) demonstrated no positive F-actin staining. Fibroblasts (B) were spindle shaped 
with intracellular F-actin bundles. Myofibroblasts (C) demonstrated strong F-actin staining 
showing prominent microfilament apparatus. Bar = 100μm 
 
 
Figure 3: Immunocytochemical staining showing expression and localization of α-SMA (green) in 
equine keratocytes, fibroblasts and myofibroblasts. Nuclei are stained blue by DAPI. Negative 
staining in keratocytes (A), sparsely positive in fibroblasts (B) and abundantly positive in 
myofibroblasts (C). Bar = 100μm 
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Figure 4: Real-time graph demonstrating the results of quantitative real-time PCR measurements 
of α-SMA in equine keratocytes, fibroblasts and myofibroblasts. A statistically significant increase 
in α-SMA was noted in myofibroblasts compared to keratocytes and fibroblasts. The asterisk 
indicates a p<0.01. 
 
 
Figure 5: Light microscopy images of both ECFs alone and ECFs after application of AAV5 at 
two time points (24 hrs and 48 hrs post application). All images demonstrate the classic normal, 
spindle shape morphology of ECFs.  ECFs alone at 24 hrs (A), ECFs + AAV5, 24 hrs after 
application of AAV5 (B), ECFs alone at 48 hrs (C), and ECFs + AAV5, 48 hrs after application of 
AAV5 (D). Calibration bar is 100 microns. 
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Figure 6: Percent viability of control ECFs and ECFs transduced with AAV5 over three time 
points: 8 hrs, 24 hrs and 48 hrs after AAV5 application. 
 
 
 
Figure 7: Panels A-C demonstrate the successful transduction of ECF by AAV5 as evidenced by 
the expression of EGFP demonstrating the classic spindle shape cellular morphology. The ECF 
nuclei are stained by blue by DAPI. Panel D shows the quantification of the data using Image J 
software and expressed as percent transduction efficiency.  
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Figure 8: Dose-dependent effect of early and late MMC treatment to ECF. Panels A and B show 
data collected with trypan blue assay and panels C and D show MTT assay data. The doses of 
MMC (0.02% or less) did not alter ECF viability whereas MMC doses higher than 0.02% showed 
mild-to-moderate toxicity.  
 
 
 
 
 
 
Figure 9: Phase-contrast light microscopy images of ECF. No morphological changes to ECF 
were observed when 0.02% of MMC early (A) or late (B) treatment was performed, thus 
establishing MMC safety to ECF in-vitro. Bar = 100μm  
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Figure 10: TUNEL assay detecting apoptosis induced by 0.02% MMC in ECF. Panel A 
demonstrates the early control of no MMC treatment, panel B shows effects of early MMC 
treatment, panel C is late control (no MMC) and panel D shows effects of late MMC treatment on 
ECF. TUNEL-positive cells are stained in red and nuclei in blue with DAPI. Arrows denote 
TUNEL-positive cells. Magnification 400x. Bar = 100μm 
 
 
 
Figure 11: Immunocytochemical staining with phalloidin showing levels of F-actin in ECF control 
group (A; no MMC treatment), in the presence of TGFβ1 (B), early MMC treatment group (C) and 
late MMC treatment group (D). F-actin stained cells are red and nuclei are stained blue with 
DAPI. Magnification 400x. Bar = 100μm 
 
 
 
Figure 12: Immunocytochemical staining of α-SMA (green) showing anti-fibrotic effects of MMC 
on ECF. Early MMC treatment (C) showed significant inhibition in TGFβ1-induced myofibroblast 
formation in ECF whereas late MMC treatment showed moderate inhibition (D). The TGFβ1 
untreated cultures did not show any α-SMA (A) while the TGFβ1 treated cultures showed 
significant α-SMA staining (B). The DAPI stained nuclei are shown in blue. Magnification 400x. 
Bar = 100μm 
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Figure 13: Quantification of α-SMA-stained cells in ECF cultures treated with or without MMC. 
Myofibroblast formation was significantly induced in the presence of TGFβ1. Early MMC 
treatment significantly decreased TGFβ1-induced myofibroblast formation in ECF compared to 
untreated controls, whereas late MMC treatment showed moderate reduction. ψ denotes p <0.01 
(Con vs TGFβ1) and * represents p<0.01 (TGFβ1 vs TGFβ1+MMC). 
 
 
Figure 14: Western blot analysis showing quantitative measurement of α-SMA (myofibroblast 
marker) in ECF treated with or without TGFβ1 (1ng/ml) and 0.02% MMC. Equal quantity of 
protein (50 μg) was loaded in each lane. GAPDH was used as house keeping gene. A single 
early MMC treatment showed significant decrease in TGFβ1-induced myofibroblast formation in 
ECF compared to untreated controls. The late MMC treatment showed moderate reduction in α-
SMA.  
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Figure 15: Quantitative real-time PCR reactions showing measurements of α-SMA in MMC 
treated or untreated ECF. TGFβ1 exposure induced significant α-SMA formation in ECF and early 
MMC treatment significantly decreased TGFβ1-induced myofibroblast formation in ECF. Late 
MMC treatment showed moderate decrease in α-SMA RNA (data not shown). ψ indicates p <0.01 
(Con vs TGFβ1) and * represents p<0.01 (TGFβ1 vs TGFβ1+MMC early). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
36 
 
BIBLIOGRAPHY 
1.Barnett K. Color Atlas and Text of Equine Ophthalmology Mosby‐Wolfe, Baltimore, 1995. 
 
2.Gilger BC. Equine ophthalmology Elsevier Saunders, St. Louis, 2005. 
 
3.Gelatt KN. Veterinary Ophthalmology 4th ed. Blackwell Publishing, 2007. 
 
4.Haber M, Cao Z, Panjwani N, Bedenice D, Li WW, Provost PJ. Effects of growth factors (EGF, 
PDGF‐BB and TGF‐beta 1) on cultured equine epithelial cells and keratocytes: implications for 
wound healing. Vet Ophthalmol. 2003; 6: 211‐217. 
 
5.Michau TM, Schwabenton B, Davidson MG, Gilger BC. Superficial, nonhealing corneal ulcers in 
horses: 23 cases (1989‐2003). Vet Ophthalmol. 2003; 6: 291‐297. 
 
6.Nasisse MP, Nelms S. Equine ulcerative keratitis. Vet Clin North Am Equine Pract. 1992; 8: 537‐
555. 
 
7.Vij N, Sharma A, Thakkar M, Sinha S, Mohan RR. PDGF‐driven proliferation, migration, and IL8 
chemokine secretion in human corneal fibroblasts involve JAK2‐STAT3 signaling pathway. Mol 
Vis. 2008; 14: 1020‐1027. 
 
8.Netto MV, Mohan RR, Ambrosio R, Jr., Hutcheon AE, Zieske JD, Wilson SE. Wound healing in 
the cornea: a review of refractive surgery complications and new prospects for therapy. Cornea. 
2005; 24: 509‐522. 
 
9.Jester JV, Petroll WM, Cavanagh HD. Corneal stromal wound healing in refractive surgery: the 
role of myofibroblasts. Prog Retin Eye Res. 1999; 18: 311‐356. 
 
10.Wilson SE, Mohan RR, Ambrosio R, Jr., Hong J, Lee J. The corneal wound healing response: 
cytokine‐mediated interaction of the epithelium, stroma, and inflammatory cells. Prog Retin Eye 
Res. 2001; 20: 625‐637. 
 
11.Netto MV, Mohan RR, Sinha S, Sharma A, Gupta PC, Wilson SE. Effect of prophylactic and 
therapeutic mitomycin C on corneal apoptosis, cellular proliferation, haze, and long‐term 
keratocyte density in rabbits. J Refract Surg. 2006; 22: 562‐574. 
 
12.Jester JV, Huang J, Barry‐Lane PA, Kao WW, Petroll WM, Cavanagh HD. Transforming growth 
factor(beta)‐mediated corneal myofibroblast differentiation requires actin and fibronectin 
assembly. Invest Ophthalmol Vis Sci. 1999; 40: 1959‐1967. 
 
13.Jester JV, Huang J, Fisher S, Spiekerman J, Chang JH, Wright WE, Shay JW. Myofibroblast 
differentiation of normal human keratocytes and hTERT, extended‐life human corneal 
fibroblasts. Invest Ophthalmol Vis Sci. 2003; 44: 1850‐1858. 
 
14.Maltseva O, Folger P, Zekaria D, Petridou S, Masur SK. Fibroblast growth factor reversal of 
the corneal myofibroblast phenotype. Invest Ophthalmol Vis Sci. 2001; 42: 2490‐2495. 
37 
 
15.Boote C, Dennis S, Newton RH, Puri H, Meek KM. Collagen fibrils appear more closely packed 
in the prepupillary cornea: optical and biomechanical implications. Invest Ophthalmol Vis Sci. 
2003; 44: 2941‐2948. 
 
16.Conrad GW, Funderburgh JL. Eye development and the appearance and maintenance of 
corneal transparency. Trans Kans Acad Sci. 1992; 95: 34‐38. 
 
17.Maurice DM. The transparency of the corneal stroma. Vision Res. 1970; 10: 107‐108. 
 
18.Mohan RR, Schultz GS, Hong JW, Wilson SE. Gene transfer into rabbit keratocytes using AAV 
and lipid‐mediated plasmid DNA vectors with a lamellar flap for stromal access. Exp Eye Res. 
2003; 76: 373‐383. 
 
19.Mohan RR, Sharma A, Netto MV, Sinha S, Wilson SE. Gene therapy in the cornea. Prog Retin 
Eye Res. 2005; 24: 537‐559. 
 
20.Verma IM, Weitzman MD. Gene therapy: twenty‐first century medicine. Annu Rev Biochem. 
2005; 74: 711‐738. 
 
21.Monahan PE, Samulski RJ. Adeno‐associated virus vectors for gene therapy: more pros than 
cons? Mol Med Today. 2000; 6: 433‐440. 
 
22.Daya S, Berns KI. Gene therapy using adeno‐associated virus vectors. Clin Microbiol Rev. 
2008; 21: 583‐593. 
 
23.Monahan PE, Samulski RJ. AAV vectors: is clinical success on the horizon? Gene Ther. 2000; 7: 
24‐30. 
 
24.Lebherz C, Maguire A, Tang W, Bennett J, Wilson JM. Novel AAV serotypes for improved 
ocular gene transfer. J Gene Med. 2008; 10: 375‐382. 
 
25.Royo NC, Vandenberghe LH, Ma JY, Hauspurg A, Yu L, Maronski M, Johnston J, Dichter MA, 
Wilson JM, Watson DJ. Specific AAV serotypes stably transduce primary hippocampal and 
cortical cultures with high efficiency and low toxicity. Brain Res. 2008; 1190: 15‐22. 
 
26.Saika S, Yamanaka O, Sumioka T, Miyamoto T, Miyazaki K, Okada Y, Kitano A, Shirai K, Tanaka 
S, Ikeda K. Fibrotic disorders in the eye: targets of gene therapy. Prog Retin Eye Res. 2008; 27: 
177‐196. 
 
27.Alexander JJ, Hauswirth WW. Adeno‐associated viral vectors and the retina. Adv Exp Med 
Biol. 2008; 613: 121‐128. 
 
28.Surace EM, Auricchio A. Versatility of AAV vectors for retinal gene transfer. Vision Res. 2008; 
48: 353‐359. 
 
29.Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, Viswanathan A, 
Holder GE, Stockman A, Tyler N, Petersen‐Jones S, Bhattacharya SS, Thrasher AJ, Fitzke FW, 
38 
 
Carter BJ, Rubin GS, Moore AT, Ali RR. Effect of gene therapy on visual function in Leber's 
congenital amaurosis. N Engl J Med. 2008; 358: 2231‐2239. 
30.Maguire AM, Simonelli F, Pierce EA, Pugh EN, Jr., Mingozzi F, Bennicelli J, Banfi S, Marshall 
KA, Testa F, Surace EM, Rossi S, Lyubarsky A, Arruda VR, Konkle B, Stone E, Sun J, Jacobs J, 
Dell'Osso L, Hertle R, Ma JX, Redmond TM, Zhu X, Hauck B, Zelenaia O, Shindler KS, Maguire MG, 
Wright JF, Volpe NJ, McDonnell JW, Auricchio A, High KA, Bennett J. Safety and efficacy of gene 
transfer for Leber's congenital amaurosis. N Engl J Med. 2008; 358: 2240‐2248. 
 
31.Auricchio A, Rolling F. Adeno‐associated viral vectors for retinal gene transfer and treatment 
of retinal diseases. Curr Gene Ther. 2005; 5: 339‐348. 
 
32.Surace EM, Domenici L, Cortese K, Cotugno G, Di Vicino U, Venturi C, Cellerino A, Marigo V, 
Tacchetti C, Ballabio A, Auricchio A. Amelioration of both functional and morphological 
abnormalities in the retina of a mouse model of ocular albinism following AAV‐mediated gene 
transfer. Mol Ther. 2005; 12: 652‐658. 
 
33.Chadderton N, Millington‐Ward S, Palfi A, O'Reilly M, Tuohy G, Humphries MM, Li T, 
Humphries P, Kenna PF, Farrar GJ. Improved retinal function in a mouse model of dominant 
retinitis pigmentosa following AAV‐delivered gene therapy. Mol Ther. 2009; 17: 593‐599. 
 
34.Van Vliet KM, Blouin V, Brument N, Agbandje‐McKenna M, Snyder RO. The role of the adeno‐
associated virus capsid in gene transfer. Methods Mol Biol. 2008; 437: 51‐91. 
 
35.Mohan RR, Hutcheon AE, Choi R, Hong J, Lee J, Ambrosio R, Jr., Zieske JD, Wilson SE. 
Apoptosis, necrosis, proliferation, and myofibroblast generation in the stroma following LASIK 
and PRK. Exp Eye Res. 2003; 76: 71‐87. 
 
36.Mohan RR, Stapleton WM, Sinha S, Netto MV, Wilson SE. A novel method for generating 
corneal haze in anterior stroma of the mouse eye with the excimer laser. Exp Eye Res. 2008; 86: 
235‐240. 
 
37.Leccisotti A. Mitomycin C in photorefractive keratectomy: effect on epithelialization and 
predictability. Cornea. 2008; 27: 288‐291. 
 
38.Mohan RR, Liang Q, Kim WJ, Helena MC, Baerveldt F, Wilson SE. Apoptosis in the cornea: 
further characterization of Fas/Fas ligand system. Exp Eye Res. 1997; 65: 575‐589. 
 
39.Galm U, Hager MH, Van Lanen SG, Ju J, Thorson JS, Shen B. Antitumor antibiotics: bleomycin, 
enediynes, and mitomycin. Chem Rev. 2005; 105: 739‐758. 
 
40.Nuyts RM, Pels E, Greve EL. The effects of 5‐fluorouracil and mitomycin C on the corneal 
endothelium. Curr Eye Res. 1992; 11: 565‐570. 
 
41.Jampel HD. Effect of brief exposure to mitomycin C on viability and proliferation of cultured 
human Tenon's capsule fibroblasts. Ophthalmology. 1992; 99: 1471‐1476. 
 
39 
 
42.Kang SG, Chung H, Yoo YD, Lee JG, Choi YI, Yu YS. Mechanism of growth inhibitory effect of 
Mitomycin‐C on cultured human retinal pigment epithelial cells: apoptosis and cell cycle arrest. 
Curr Eye Res. 2001; 22: 174‐181. 
 
43.Wu KY, Hong SJ, Huang HT, Lin CP, Chen CW. Toxic effects of mitomycin‐C on cultured 
corneal keratocytes and endothelial cells. J Ocul Pharmacol Ther. 1999; 15: 401‐411. 
 
44.Thornton I, Xu M, Krueger RR. Comparison of standard (0.02%) and low dose (0.002%) 
mitomycin C in the prevention of corneal haze following surface ablation for myopia. Journal of 
Refractive Surgery. 2008; 24: S68‐76. 
 
45.Srinivasan S, Drake A, Herzig S. Photorefractive keratectomy with 0.02% mitomycin C for 
treatment of residual refractive errors after LASIK. Journal of Refractive Surgery. 2008; 24: S64‐
67. 
 
46.Shalaby A, Kaye GB, Gimbel HV. Mitomycin C in photorefractive keratectomy. Journal of 
Refractive Surgery. 2009; 25: S93‐97. 
 
47.Rajan MS, O'Brart DP, Patmore A, Marshall J. Cellular effects of mitomycin‐C on human 
corneas after photorefractive keratectomy. J Cataract Refract Surg. 2006; 32: 1741‐1747. 
 
48.Nassaralla BA, McLeod SD, Nassaralla JJ, Jr. Prophylactic mitomycin C to inhibit corneal haze 
after photorefractive keratectomy for residual myopia following radial keratotomy. J Refract 
Surg. 2007; 23: 226‐232. 
 
49.Brooks DE. Equine Ophthalmology in Veterinary ophthalmology. 4th ed. Blackwell Pub., 
Ames, Iowa, 2007. 
 
50.Leccisotti A. Photorefractive keratectomy with mitomycin C after deep anterior lamellar 
keratoplasty for keratoconus. Cornea. 2008; 27: 417‐420. 
 
51.Sharma A, Mehan MM, Sinha S, Cowden JW, Mohan RR. Trichostatin a inhibits corneal haze 
in vitro and in vivo. Investigative Ophthalmology and Visual Science. 2009; 50: 2695‐2701. 
 
52.Mohan R, Stapleton, WM, Sinha, S, Netto, MV. Decorin gene transfer into keratocytes inhibits 
alpha smooth muscle actin (SMA) expression and myofibroblast transformation. In: abstract. 
ARVO #1815, 2006. 
 
53.Barnett KC. Equine ophthalmology : an atlas and text. 2nd ed. Saunders, Edinburgh ; New 
York, 2004. 
 
54.Masur SK, Dewal HS, Dinh TT, Erenburg I, Petridou S. Myofibroblasts differentiate from 
fibroblasts when plated at low density. Proc Natl Acad Sci U S A. 1996; 93: 4219‐4223. 
 
55.Hong JW LJ, Lee JS, Mohan RR, Woods DJ, He YG, Wilson SE. Proinflammatory chemokine 
induction in keratocytes and inflammatory cell infiltration into the cornea. Investigative 
Ophthalmology and Visual Science. 2001; 42: 2795‐2803. 
 
40 
 
56.Masur SK, Cheung JK, Antohi S. Identification of integrins in cultured corneal fibroblasts and 
in isolated keratocytes. Invest Ophthalmol Vis Sci. 1993; 34: 2690‐2698. 
 
57.Werner A, Braun M, Kietzmann M. Isolation and cultivation of canine corneal cells for in vitro 
studies on the anti‐inflammatory effects of dexamethasone. Vet Ophthalmol. 2008; 11: 67‐74. 
58.Werner A, Braun M, Reichl S, Kietzmann M. Establishing and functional testing of a canine 
corneal construct. Vet Ophthalmol. 2008; 11: 280‐289. 
 
59.Tegtmeyer S, Papantoniou I, Muller‐Goymann CC. Reconstruction of an in vitro cornea and its 
use for drug permeation studies from different formulations containing pilocarpine 
hydrochloride. Eur J Pharm Biopharm. 2001; 51: 119‐125. 
 
60.Toropainen E, Ranta VP, Talvitie A, Suhonen P, Urtti A. Culture model of human corneal 
epithelium for prediction of ocular drug absorption. Invest Ophthalmol Vis Sci. 2001; 42: 2942‐
2948. 
 
61.Netto MV, Mohan RR, Sinha S, Sharma A, Dupps W, Wilson SE. Stromal haze, myofibroblasts, 
and surface irregularity after PRK. Exp Eye Res. 2006; 82: 788‐797. 
 
62.Jester JV, Moller‐Pedersen T, Huang J, Sax CM, Kays WT, Cavangh HD, Petroll WM, Piatigorsky 
J. The cellular basis of corneal transparency: evidence for 'corneal crystallins'. J Cell Sci. 1999; 
112 ( Pt 5): 613‐622. 
 
63.Polyak S, Mah C, Porvasnik S, Herlihy JD, Campbell‐Thompson M, Byrne BJ, Valentine JF. Gene 
delivery to intestinal epithelial cells in vitro and in vivo with recombinant adeno‐associated virus 
types 1, 2 and 5. Dig Dis Sci. 2008; 53: 1261‐1270. 
 
64.Ghosh A, Yue Y, Duan D. Viral serotype and the transgene sequence influence overlapping 
adeno‐associated viral (AAV) vector‐mediated gene transfer in skeletal muscle. J Gene Med. 
2006; 8: 298‐305. 
 
65.Limberis MP, Vandenberghe LH, Zhang L, Pickles RJ, Wilson JM. Transduction efficiencies of 
novel AAV vectors in mouse airway epithelium in vivo and human ciliated airway epithelium in 
vitro. Mol Ther. 2009; 17: 294‐301. 
 
66.Buss DG, Giuliano EA, Sharma A, Mohan RR. Isolation and cultivation of equine corneal 
keratocytes, fibroblasts and myofibroblasts. Veterinary Ophthalmology. 2010; 13. 
 
67.Louboutin JP, Wang L, Wilson JM. Gene transfer into skeletal muscle using novel AAV 
serotypes. J Gene Med. 2005; 7: 442‐451. 
 
68.Gao G, Lu Y, Calcedo R, Grant RL, Bell P, Wang L, Figueredo J, Lock M, Wilson JM. Biology of 
AAV serotype vectors in liver‐directed gene transfer to nonhuman primates. Mol Ther. 2006; 13: 
77‐87. 
 
69.Morrison DF, Foss DL, Murtaugh MP. Interleukin‐10 gene therapy‐mediated amelioration of 
bacterial pneumonia. Infect Immun. 2000; 68: 4752‐4758. 
 
41 
 
70.Greenberger MJ, Kunkel SL, Strieter RM, Lukacs NW, Bramson J, Gauldie J, Graham FL, Hitt M, 
Danforth JM, Standiford TJ. IL‐12 gene therapy protects mice in lethal Klebsiella pneumonia. J 
Immunol. 1996; 157: 3006‐3012. 
 
71.Sharma A, Ghosh A, Siddappa C, Mohan R. Ocular Surface: Gene Therapy. Encyclopedia of 
the Eye. 2009; In Press. 
72.Wilson SE, Mohan RR, Hong JW, Lee JS, Choi R. The wound healing response after laser in situ 
keratomileusis and photorefractive keratectomy: elusive control of biological variability and 
effect on custom laser vision correction. Archives of Ophthalmology. 2001; 119: 889‐896. 
 
73.Chen C, Michelini‐Norris B, Stevens S, Rowsey J, Ren X, Goldstein M, Schultz G. Measurement 
of mRNAs for TGFss and extracellular matrix proteins in corneas of rats after PRK. Investigative 
Ophthalmology and Visual Science. 2000; 41: 4108‐4116. 
 
74.Tuli SS, Liu R, Chen C, Blalock TD, Goldstein M, Schultz GS. Immunohistochemical localization 
of EGF, TGF‐alpha, TGF‐beta, and their receptors in rat corneas during healing of excimer laser 
ablation. Current Eye Research. 2006; 31: 709‐719. 
 
75.Moller‐Pedersen T, Cavanagh HD, Petroll WM, Jester JV. Neutralizing antibody to TGFbeta 
modulates stromal fibrosis but not regression of photoablative effect following PRK. Current Eye 
Research. 1998; 17: 736‐747. 
 
76.Rayner SG, Van Zyl N. The use of mitomycin C as an adjunctive treatment for equine ocular 
squamous cell carcinoma. Australian Veterinary Journal. 2006; 84: 43‐46. 
 
77.Buss DG, Sharma A, Giuliano EA, Mohan RR. Gene delivery in the equine cornea: a novel 
therapeutic strategy. Veterinary Ophthalmology. 2010; In Press. 
 
78.Majmudar PA, Forstot SL, Dennis RF, Nirankari VS, Damiano RE, Brenart R, Epstein RJ. Topical 
mitomycin‐C for subepithelial fibrosis after refractive corneal surgery. Ophthalmology. 2000; 
107: 89‐94. 
 
